$11.64 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Serica

SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. It uses its technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Its SQZ Antigen Presenting Cells (SQZ APC) platform is in a Phase I trial in highly immunogenic (HPV) plus tumors. It is also developing SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). Its SQZ APC platform is focused on generating robust (cluster of differentiation 8 (CD8) plus T cell responses. Its lead product candidate, SQZ- peripheral blood mononuclear cells (PBMC)-HPV, from its SQZ APC platform, is a targeted cancer vaccine that has been designed to generate antigen-specific CD8 plus T cell responses to attack HPV plus tumors.

Stock Analysis

last close $12.18
1-mo return -14.1%
3-mo return -6.7%
avg daily vol. 65.57T
52-week high 36.49
52-week low 11.15
market cap. $342M
forward pe -
annual div. -
roe -214.2%
ltg forecast 37%
dividend yield -
annual rev. $19M
inst own. 73%

Subscribe now for daily local and international financial news